Magnitude of the Age-Advancement Effect of Comorbidities in Colorectal Cancer Prognosis.
Authors: Boakye D, Walter V, Jansen L, Martens UM, Chang-Claude J, Hoffmeister M, Brenner H Abstract BACKGROUND: Comorbidities and old age independently compromise prognosis of patients with colorectal cancer (CRC). The impact of comorbidities could thus be considered as conveying worse prognosis already at younger ages, but evidence is lacking on how much worsening of prognosis with age is advanced to younger ages in comorbid versus noncomorbid patients. We aimed to quantify, for the first time, the impact of comorbidities on CRC prognosis in "age advancement" of worse prognosis. METHODS: A total of ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia.
Authors: Patel SH, Vasu S, Guo L, Lemaster O, Byrd JC, Walker A Abstract Acute undifferentiated leukemia (AUL) is a subtype of acute leukemias of ambiguous lineage. There is no standard treatment approach for AUL, although acute lymphoblastic leukemia-like regimens for induction therapy have been used. Additional data suggest that AUL may be better treated as acute myeloid leukemia (AML), given their similarities in genetic, cytogenetic, and gene expression patterns. Somatic mutations of IDH1 are found in 7% to 14% of patients with AML; however, the patient in this study was the first patient with IDH1-mutated AUL ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Alcohol Use Among Patients With Cancer and Survivors in the United States, 2000-2017.
Authors: Sanford NN, Sher DJ, Xu X, Ahn C, D'Amico AV, Aizer AA, Mahal BA Abstract BACKGROUND: Alcohol use is an established risk factor for several malignancies and is associated with adverse oncologic outcomes among individuals diagnosed with cancer. The prevalence and patterns of alcohol use among cancer survivors are poorly described. METHODS: We used the National Health Interview Survey from 2000 to 2017 to examine alcohol drinking prevalence and patterns among adults reporting a cancer diagnosis. Multivariable logistic regression was used to define the association between demographic and socioeconomic var...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

This Time I Mean It!
Authors: Tempero M PMID: 31910382 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?
Authors: Li T PMID: 31910383 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Authors: Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA Abstract Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials.
CONCLUSIONS: The RRs were not different between non-RCTs and RCTs of cancer drugs approved based on changes to a biomarker, but the DoRs in non-RCTs were significantly higher than in RCTs. Caution must be exercised when approving or prescribing targeted drugs based on data on durable responses derived from non-RCTs, because the responses could be overestimates and poor predictors of survival benefit. PMID: 31910385 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

High-Cost Patients and Preventable Spending: A Population-Based Study.
CONCLUSIONS: HC patients with cancer are a unique subpopulation. Given the type of care they receive, there seems to be limited scope to prevent acute care spending among this patient group. To reduce costs, other strategies, such as making hospital care more efficient and generating less costly encounters involving chemotherapy, should be explored. PMID: 31910386 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy.
CONCLUSIONS: Tumor stage and its substages represent extremely important determinants of prognosis after lengthy event-free follow-up. The recorded observations have critical importance for physicians regarding patient follow-up and counseling. PMID: 31910387 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis.
This study examined the role, optimal regimen, and duration of AC using data from the largest integrated health system in the United States. PATIENTS AND METHODS: Using the Veterans Affairs Central Cancer Registry, patients with stage II-III rectal cancer diagnosed in 2001 through 2011 who received neoadjuvant CRT and surgery with or without AC were identified. Kaplan-Meier analysis, log-rank tests, and propensity score (PS) adjustment analysis were used to assess survival. RESULTS: A total of 866 patients were identified; 417 received AC and 449 did not (observation [OBS] group). Median follow-up was 109 months. M...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Authors: Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba N Abstract Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for pat...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 9, 2020 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Authors: Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA Abstract Testicular cancer is relatively uncommon and accounts for 50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs. PMID: ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.
Authors: Khaki AR, Gadi VK, Prasad V PMID: 31805524 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Addressing Knowledge Gaps in Acute Myeloid Leukemia to Improve Referral for Hematopoietic Cell Transplantation Consultation.
CONCLUSIONS: The webinars met the educational needs of learners and improved knowledge gaps. This study provided novel insights into the learning needs of clinicians who care for patients with AML and a roadmap for future educational interventions. PMID: 31805525 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.
Authors: Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, OCN, Hughes M Abstract The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of th...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Testicular Cancer Survivorship.
Authors: Fung C, Dinh PC, Fossa SD, Travis LB Abstract Testicular cancer (TC) is the most common cancer among men aged 18 to 39 years. It is highly curable, with a 10-year relative survival approaching 95% due to effective cisplatin-based chemotherapy. Given the increasing incidence of TC and improved survival, TC survivors (TCS) now account for approximately 4% of all US male cancer survivors. They have also become a valuable cohort for adult-onset cancer survivorship research, given their prolonged survival. Commensurately, long-term treatment-related complications have emerged as important survivorship issues. T...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
CONCLUSIONS: Based on the ASCO-VF algorithm, HR PFS-, mPFS-, and RR-derived CBS are suboptimal surrogates, because they were shown to be biased and poorly correlated to HR OS-derived CBS. Despite lower weighting than OS in the ASCO-VF algorithm, PFS still overestimated CBS. Simple rescaling of surrogate endpoints may not improve their validity within the ASCO-VF given their poor correlations with HR OS-derived CBS. PMID: 31805528 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion.
This report describes a woman aged 22 years with unresectable ALK-negative IMT. Next-generation sequencing revealed a TFG-ROS1 fusion, and she had a partial response to the ROS1 inhibitor ceritinib. This report provides the first published demonstration of a patient with IMT with ROS1 fusion successfully treated using ceritinib. Our study suggests that targeting ROS1 fusions using the small molecule inhibitor shows promise as an effective therapy in patients with IMT carrying this genetic alteration, but this requires further investigation in large clinical trials. PMID: 31805529 [PubMed - in process] (Source: Journal ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Quantitative Imaging Assessment for Clinical Trials in Oncology.
CONCLUSIONS: Medical oncologists burdened with the task of tumor measurements in patients on clinical trials may introduce significant variability and investigator bias, with the potential to affect therapeutic response and clinical trial outcomes. Institutional imaging cores may help bridge the gap by providing unbiased and reproducible measurements and enable a leaner workflow. PMID: 31805530 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Santa, Can You Hear Me?
Authors: Tempero M PMID: 31805531 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

High-Value Cancer Care and the Problem With Surrogate Endpoints in the Quality/Cost Equation.
Authors: Chino F PMID: 31805532 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Changes in Management of Left-Sided Obstructive Colon Cancer: National Practice and Guideline Implementation.
Authors: Veld JV, Amelung FJ, Borstlap WAA, Eise van Halsema E, Consten ECJ, Siersema PD, Ter Borg F, Silvester van der Zaag E, Fockens P, Bemelman WA, Elise van Hooft J, Tanis PJ, Dutch Snapshot Research Group Abstract BACKGROUND: Previous analysis of Dutch practice in treatment of left-sided obstructive colon cancer (LSOCC) until 2012 showed that emergency resection (ER) was preferred, with high mortality in patients aged ≥70 years. Consequently, Dutch and European guidelines in 2014 recommended a bridge to surgery (BTS) with either self-expandable metal stent (SEMS) or decompressing stoma (DS) in high-risk pa...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy.
CONCLUSIONS: In men receiving definitive RT for intermediate- or high-risk PCa, CAB was not associated with improved PCSM or OS compared with GnRH alone. PMID: 31805534 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery.
CONCLUSIONS: Subdivision of M1 stage facilitates prognosis prediction and treatment planning for patients with de novo MBC. Treatment offered should be decided in a coordinated multidisciplinary setting. Primary tumor surgery may play an important role in the management of selected patients. PMID: 31805535 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - December 6, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Therapeutic Advances in First-Line Management of Acute Myeloid Leukemia.
Authors: Pollyea DA Abstract Over the past several years, drug approvals for first-line treatment of acute myeloid leukemia have changed the landscape from a "wasteland" to an "embarrassment of riches." In general, patients deemed "fit" for induction chemotherapy who have a core-binding factor abnormality should receive 7 + 3 in combination with gemtuzumab, 7 + 3 with midostaurin for those with an FLT3 abnormality, and liposomal cytarabine + daunorubicin for patients with secondary AML. Although other options exist, Dr. Daniel A. Pollyea recommended a venetoclax/azacitidine regimen for...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond.
Authors: Park J Abstract Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved survival compared with chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL), and are now standard of care in the relapsed setting. However, most adult patients still die of ALL despite these therapies, with or without hematopoietic stem cell transplant. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jae Park summarized clinical data from key trials of novel immunotherapies in ALL and reviewed evidence-based treatment ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

The NCCN 2019 Annual Congress: Hematologic Malignancies.
Authors: Carlson RW PMID: 31766015 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Updates in Treatment Strategies for Hodgkin Lymphoma.
Authors: Advani RH Abstract Several options are available for frontline treatment of advanced-stage Hodgkin lymphoma (HL) and treatment of relapsed HL, each with inherent advantages and disadvantages. Clinicians must balance risk with benefit for the individual patient. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Ranjana H. Advani summarized the current frontline treatment options for advanced-stage HL and outlined novel and emerging agents that may be incorporated as therapy options for relapsed disease. PMID: 31766016 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?
Authors: Fisher RI Abstract Over the past several decades, tremendous progress has been made in the treatment of follicular lymphoma. The addition of rituximab to chemotherapy led to significant improvements in survival in the 1990s. Current standard of care in advanced-stage, previously untreated follicular lymphoma is rituximab plus chemotherapy, sometimes followed by rituximab maintenance. Now, as more research is conducted in the field of chemotherapy-free treatment, Dr. Richard I. Fisher discussed the importance of carefully constructed phase II or III trials at the NCCN 2019 Annual Congress: Hematologic Malig...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Diagnosis and Management of Castleman Disease.
Authors: Abramson JS Abstract Castleman disease is a heterogeneous nonmalignant lymphoproliferative disorder. Major distinctions include unicentric versus multicentric presentation; hyaline vascular, plasmacytic, or mixed pathology; and HHV8-associated (typically HIV-positive) versus idiopathic disease. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jeremy S. Abramson stated that rituximab is preferred as initial therapy for HHV8-positive disease, and chemotherapy can be added for patients with fulminant disease (antiretrovirals should always be used as well for those who are HIV-positive). Siltuxi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?
Authors: Brown JR, Wierda WG Abstract With the enormous progress made in treatment and management, many oncologists have called this the golden age of chronic lymphocytic leukemia (CLL). The past few years alone have seen the approval of multiple agents, including small molecule inhibitors that have led to longer, more durable periods of disease control. However, the introduction of these new drugs into the armamentarium has raised an important question regarding standard of care: is there still a role for chemoimmunotherapy in the first-line setting? At the NCCN 2019 Annual Congress: Hematologic Malignancies, Drs....
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last?
Authors: Efebera YA, Shah N Abstract The number of approved regimens for multiple myeloma has increased dramatically in recent years, improving progression-free and overall survival while also increasing the complexity of treatment decisions. Despite the plethora of options available, one fundamental treatment question remains: How long should initial therapy last? At the NCCN 2019 Annual Congress: Hematologic Malignancies, Drs. Yvonne A. Efebera and Nina Shah debated whether myeloma therapy should be time-limited or continue until disease progression. PMID: 31766020 [PubMed - in process] (Source: Journal of th...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know.
Authors: Zelenetz AD Abstract Although complex, biologic agents are key components of modern therapy in multiple disciplines, particularly oncology. However, despite the fact that biosimilars (eg, filgrastim-sndz, bevacizumab-awwb, trastuzumab-dkst, rituximab-abbs) have been approved in the United States, many clinicians are poorly informed about their unique pathway for approval. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, outlined important issues regarding the use of biosimilars, including extrapolation, interchangeability, and namin...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Evolution of Therapy for Relapsed/Refractory Multiple Myeloma.
Authors: Castillo JJ Abstract With so many recent advances in relapsed/refractory multiple myeloma, keeping abreast with current treatment recommendations can be challenging. Novel immunomodulators, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, and nuclear export inhibitors have all been added to the armamentarium, and the choice of which of these drugs or drug combinations to use depends on individual disease-related and patient-related factors, previous therapies, and treatment toxicities. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jorge J. Castillo provided an...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes.
Authors: Bejar R Abstract Often unrecognized and underdiagnosed, myelodysplastic syndromes (MDS) are a rare group of cancers in which the bone marrow fails to produce sufficient healthy blood cells. Although patients with lower-risk MDS can live for>5 years, those with high-risk disease that evolves into acute myeloid leukemia is associated with significantly lower overall survival. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Rafael Bejar summarized current standard treatment options for patients with MDS and discussed the importance of genetic testing to identify mutations that may impact tr...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 26, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Giving Thanks.
Authors: Tempero M PMID: 31693979 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.
Authors: Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, CGC, Hammond LJ, Zuccarino-Catania G Abstract The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies.
Authors: Mazzone E, Knipper S, Mistretta FA, Palumbo C, Tian Z, Gallina A, Tilki D, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz PI Abstract BACKGROUND: Use of inpatient palliative care (IPC) in the treatment of advanced cancer represents a well-established guideline recommendation. A recent analysis showed that patients with genitourinary cancer benefit from IPC at the second lowest rate among 4 examined primary cancers, namely lung, breast, colorectal, and genitourinary. Based on this observation, temporal trends and predictors of IPC use were examined in patients with metastatic urothelial carcinoma o...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population.
CONCLUSIONS: Although PET use remains appropriately low, many patients with stage I-II colon cancer do not receive appropriate staging and surveillance CT chest scans. Among those who do receive these scans during surveillance, high use has declined significantly over time. PMID: 31693982 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Mortality After Invasive Second Breast Cancers Following Prior Radiotherapy for DCIS.
This study sought to evaluate the impact of RT for DCIS on mortality after SBC in a larger cohort. PATIENTS AND METHODS: Using the SEER database, 3,407 patients were identified who received breast-conserving therapy with or without RT for primary DCIS in 2000 through 2013 and subsequently developed a stage I-III invasive SBC within the same time period. Fine-Gray competing risk models were used to study the association between receipt of RT and mortality after SBC. RESULTS: Prior RT was found to be associated with higher rates of breast cancer-specific mortality (hazard ratio [HR], 1.70; 95% CI, 1.18-2.45; P=.005),...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment.
CONCLUSIONS: Among California women diagnosed with OC, living closer to a high-quality center was associated with receiving adherent care. Non-Hispanic black women were less likely to receive adherent care, and women with lower SES lived farthest from high-quality hospitals. Geographic location in California is an independent predictor of adherence to NCCN Guidelines for OC. PMID: 31693984 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Coordination of Genetic Care: More Important and Complicated Than it Seems.
This report presents a case illustrating the potential errors that can occur when genetic care is fragmented and not coordinated, including ordering too much or not enough genetic testing, failing to communicate with the family who is at potential genetic risk, failing to communicate what the results of testing mean, and failing to recommend appropriate care, which may lead to psychosocial distress and late-detected cancers. This case highlights the complexities of genetic care and why management by a genetics professional results in more fiscally responsible care, appropriate genetic testing, and comprehensive care for al...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Clinical Trial Accrual at Initial Course of Therapy for Cancer and Its Impact on Survival.
Authors: Zaorsky NG, Zhang Y, Walter V, Tchelebi LT, Chinchilli VM, Gusani NJ Abstract BACKGROUND: This retrospective cohort study sought to characterize the accrual of patients with cancer into clinical trials at the time of diagnosis and analyze the impact of accrual on survival. METHODS: The National Cancer Database (NCDB) was queried for patients enrolled in clinical trials at their initial course of treatment for 46 cancers from 2004 through 2015. Descriptive statistics were used to characterize the accrual of patients with cancer in clinical trials at diagnosis, and Kaplan-Meier graphical displays, log-ra...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma.
Authors: Sanford NN, Aguilera TA, Folkert MR, Ahn C, Mahal BA, Zeh H, Beg MS, Mansour J, Sher DJ Abstract BACKGROUND: Adjuvant therapy for resected pancreatic adenocarcinoma was given a category 1 NCCN recommendation in 2000, yet many patients do not receive chemotherapy after definitive surgery. Whether sociodemographic disparities exist for receipt of adjuvant chemotherapy is poorly understood. METHODS: The National Cancer Database was used to identify patients diagnosed with nonmetastatic pancreatic adenocarcinoma who underwent definitive surgery from 2004 through 2015. Multivariable logistic regression defi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia.
Authors: Elias KM, Berkowitz RS, Horowitz NS Abstract Gestational trophoblastic disease refers to a series of interrelated tumors arising from the placenta, including benign molar pregnancies as well as the malignant conditions termed gestational trophoblastic neoplasia (GTN). GTN most commonly follows a molar pregnancy but may develop after any gestation. The wide availability of first trimester ultrasound and serum human chorionic gonadotropin (hCG) measurement has changed the presentation of molar pregnancy in recent decades from a second trimester to a first trimester disease, such that most patients have few s...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Association Between Hospital Volume, Therapy Types, and Overall Survival in Stage III and IV Cutaneous Malignant Melanoma.
This study evaluated the therapeutic and survival disparities among patients with advanced MMel based on hospital volume using the National Cancer Database (NCDB). METHODS: A retrospective analysis using regression models and Kaplan-Meier estimates was performed from the data obtained from the NCDB on patients with MMel diagnosed in 2004 through 2015. RESULTS: A total of 40,676 patients with MMel were treated at 1,260 facilities. Multivariable analysis showed that facility volume was an independent predictor of overall survival (P
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Cancer Clinical Trial Enrollment: OK Doc, but What's in It for Me?
Authors: Soo-Min Park H PMID: 31693990 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Authors: Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Wyse E, McMillian NR, Scavone J Abstract Gestational trophoblastic neoplasia (GTN), a subset of gestational trophoblastic disease (GTD), occurs when tumors develop in the cells that would normally form the placenta during pregnancy. The NCCN Guidelines for Gestational Trophoblastic Neoplasia provides treatment recom...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - November 8, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML.
CONCLUSIONS: A dramatic shift was seen in CML treatments away from traditional, nonoral chemotherapy toward use of novel oral TKIs between 2000 and 2017. As the costs of oral anticancer agents reach new highs, studies assessing the long-term health and financial outcomes among patients with CML are warranted. PMID: 31590146 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 9, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes.
CONCLUSIONS: Evidence showed that financial burdens are common, disproportionately impacting younger and socioeconomically disadvantaged patients with cancer, across disease sites, and are associated with worse treatment adherence and HRQoL. Available evidence helped identify vulnerable patients needing oncology provider engagement and response, but evidence is critically needed on the effectiveness of interventions designed to mitigate financial burden and impact. PMID: 31590147 [PubMed - in process] (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 9, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research